14 terminated. 14 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Terminated 14 |
| Phase 2 | 5 | Terminated 5 |
Follow Hyperinsulinism: new trials by email Literature Review of Hyperinsulinism trials Research Report on Hyperinsulinism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Diazoxide Suppression Test P&F Study Diazoxide, 3 mg/kg per dose - Insulin Resistance, Hyperinsulinemia | Phase 1 | Terminated | Columbia University | 1 | 2024-10-23 | 2026-08-07 |
| A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM ALN-KHK, Placebo - Type 2 Diabetes Mellitus (T2DM) | Phase 1 / Phase 2 | Terminated | Alnylam Pharmaceuticals | 49 | 2023-03-10 | 2025-05-07 |
| Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma Roflumilast, Placebo - Asthma | Phase 1 | Terminated | University of California, Davis | 5 | 2019-01-21 | 2023-10-24 |
| Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression. UCMSCs, BMMSCs, Placebo - Endothelial Dysfunction, Metabolic Syndrome | Phase 1 / Phase 2 | Terminated | Joshua M Hare | 14 | 2018-04-12 | 2022-11-08 |
| Pharmacogenomics of GLP1 Receptor Agonists Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT) - Type 2 Diabetes | Phase 1 | Terminated | University of Maryland, Baltimore | 63 | 2016-06-01 | 2025-07-01 |
| The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome TA-65, Placebo - Metabolic Syndrome, Insulin Resistance | Phase 1 | Terminated | University of Connecticut | 13 | 2013-01-01 | 2015-05-28 |
| Molecular Regulation of Muscle Glucose Metabolism U100 Humulin, Exercise - Obesity, Type 2 Diabetes Mellitus | Phase 1 | Terminated | Mayo Clinic | 48 | 2012-04-01 | 2017-11-27 |
| Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS) Salsalate - Polycystic Ovary Syndrome | Phase 1 | Terminated | Indiana University | 47 | 2012-02-01 | 2017-02-10 |
| Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates glucagon like peptide-1, glucose control - Type 2 Diabetes | Phase 1 / Phase 2 | Terminated | Albert Einstein College of Medicine | 20 | 2010-08-12 | 2024-02-28 |
| Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes Tadalafil - Type 2 Diabetes | Phase 1 | Terminated | Vastra Gotaland Region | 22 | 2009-11-01 | 2020-02-12 |
| Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia Exendin (9-39), Vehicle - Congenital Hyperinsulinism | Phase 1 / Phase 2 | Terminated | Diva De Leon | 14 | 2009-08-26 | 2020-06-01 |
| Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome Cinnamon Supplementation, Placebo (wheat flour) - Polycystic Ovary Syndrome, Insulin Resistance | Phase 1 | Terminated | Pennington Biomedical Research Center | 8 | 2009-08-01 | 2021-08-25 |
| Treatment of Type 2 Diabetes Mellitus by Duodenal Exclusion Associated With Omentectomy: Clinical and Hormonal Study Duodenal exclusion plus omentectomy, Duodenal exclusion without omentectomy - Diabetes Mellitus, Type 2, Insulin Resistance | Phase 1 / Phase 2 | Terminated | University of Campinas, Brazil | 6 | 2007-07-01 | 2010-07-23 |
| Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome Zoladex, Testosterone gel, Anastrozole Pill - Metabolic Syndrome | Phase 1 | Terminated | Massachusetts General Hospital | 66 | 2006-09-01 | 2017-04-18 |
Insulin Resistance (10) · Diabetes Mellitus, Type 2 (7) · Obesity (5) · Metabolic Syndrome (3) · Hypoglycemia (2) · Overweight (2) · Polycystic Ovary Syndrome (2) · Asthma (1) · Congenital Hyperinsulinism (1) · Diabetes Mellitus (1) · Glucose Metabolism Disorders (1) · Hyperandrogenism (1) · Infant, Newborn, Diseases (1) · Inflammation (1)
Nutritional and Metabolic Diseases (14) · Glucose Metabolism Disorders (13) · Metabolic Diseases (13) · Endocrine System Diseases (10) · Diabetes Mellitus (7) · Pathological Conditions, Signs and Symptoms (6) · Body Weight (5) · Nutrition Disorders (5) · Overnutrition (5) · Signs and Symptoms (5) · Overweight (3) · Adnexal Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Cysts (2)
Anastrozole (1) · Diazoxide (1) · Exenatide (1) · Exercise (1) · Flour (1) · Glucagon-Like Peptide 1 (1) · Glycemic Control (1) · Goserelin (1) · Incretins (1) · Insulin (1) · Insulin, Regular, Human (1) · Roflumilast (1) · Tadalafil (1) · Testosterone (1) · exendin (9-39) (1)
Albert Einstein College of Medicine (1) · Alnylam Pharmaceuticals (1) · Columbia University (1) · Diva De Leon (1) · Indiana University (1) · Joshua M Hare (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · Pennington Biomedical Research Center (1) · University of California, Davis (1) · University of Campinas, Brazil (1) · University of Connecticut (1) · University of Maryland, Baltimore (1) · Vastra Gotaland Region (1)
United States (12) · Brazil (1) · Canada (1) · Sweden (1)
Bruno Geloneze, MD, PhD (1) · Daniel T Stein, MD (1) · Diva D De Leon, MD MSCE (1) · Frances J Hayes, MD (1) · Joshua M Hare, MD (1) · Joshua R Cook, MD, PhD (1) · Lawrence J. Mandarino, PhD (1) · Leanne Redman, PhD (1) · Lori Roust, MD (1) · Maria-Luz Fernandez, Ph.D. (1) · Nicholas Kenyon, MD (1) · Per-Anders Jansson, MD, PhD (1)
PMID 19475464, PMID 30590569, PMID 32140727, PMID 32325487, PMID 38700326, PMID 41388232
R01DK061644 (1)